Safety and efficacy of ORM-12741 on cognitive and behavioural symptoms in patients with Alzheimer's disease: A randomised, double-blind, placebo-controlled, parallel group, multicentre study of 12 weeks.

Trial Profile

Safety and efficacy of ORM-12741 on cognitive and behavioural symptoms in patients with Alzheimer's disease: A randomised, double-blind, placebo-controlled, parallel group, multicentre study of 12 weeks.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2013

At a glance

  • Drugs ORM 12741 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Acronyms ALPO
  • Sponsors Orion; Orion Pharma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Sep 2013 Results presented at the 21st World Congress of Neurology.
    • 23 Mar 2013 Results presented at the 65th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top